Intranasal Application of Vasopressin Fails to Elicit Changes in Brain Immediate Early Gene Expression, Neural Activity and Behavioural Performance of Rats

Journal of Neuroendocrinology

Volumn 25, Issue 7, 2013, Pages 655-667

  Ludwig, M ^a   Tobin, V A ^a   Callahan, M F ^b   Papadaki, E ^a   Becker, A ^c   Engelmann, M ^c,d   Leng, G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF MISSOURI   (United States)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d Center for Behavioral Brain Science (CBBS)   (Germany)

Author keywords

Behaviour; Blood pressure; C Fos; Mitral cells; Olfactory bulb intranasal; Oxytocin; Vasopressin

Indexed keywords

OXYTOCIN; PROTEIN C FOS; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; BLOOD PRESSURE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN NERVE CELL; CELL ACTIVITY; CONTROLLED STUDY; ELECTRIC ACTIVITY; GENE EXPRESSION; HEART RATE; IN VIVO STUDY; MALE; MAZE TEST; MITRAL CELL; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHORT TERM MEMORY; SOCIAL DISCRIMINATION; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMEDIATE EARLY GENE; INTRANASAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BEHAVIOR, ANIMAL; GENE EXPRESSION REGULATION; GENES, IMMEDIATE-EARLY; MALE; RATS; RATS, SPRAGUE-DAWLEY; VASOPRESSINS;

EID: 84879188428     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12046     Document Type: Article

References (73)

1. Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010; 65: 768-779.
2. Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009; 30: 548-557.
3. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011; 12: 524-538.
4. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012; 35: 649-659.
5. Ermisch A, Ruhle HJ, Landgraf R, Hess J. Blood-brain barrier and peptides. J Cereb Blood Flow Metab 1985; 5: 350-357.
6. Landgraf R. Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp Clin Endocrinol 1985; 85: 245-248.
7. Newton M, Egli GE. The effect of intranasal administration of oxytocin on the let-down of milk in lactating women. Am J Obstet Gynecol 1958; 76: 103-107.
8. Hendricks CH, Gabel RA. Use of intranasal oxytocin in obstetrics. 1. A laboratory evaluation. Am J Obstet Gynecol 1960; 79: 780-788.
9. Seckl JR, Dunger DB. Diabetes insipidus. Current treatment recommendations. Drugs 1992; 44: 216-224.
10. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol 1987; 115: 307-312.
11. Guastella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav 2012; 61: 410-418.
12. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-516.
13. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012; 61: 392-399.
14. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci Biobehav Rev 1996; 20: 341-358.
15. Giri PR, Dave JR, Tabakoff B, Hoffman PL. Arginine vasopressin induces the expression of c-fos in the mouse septum and hippocampus. Mol Brain Res 1990; 7: 131-137.
16. Andreae LC, Herbert J. Expression of c-fos in restricted areas of the basal forebrain and brainstem following single or combined intraventricular infusions of vasopressin and corticotropin-releasing factor. Neuroscience 1993; 53: 735-748.
17. Olson BR, Freilino M, Hoffman GE, Stricker EM, Sved AF, Verbalis JG. c-Fos expression in rat brain and brainstem nuclei in response to treatments that alter food intake and gastric motility. Mol Cell Neurosci 1993; 4: 93-106.
18. Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci 2004; 24: 2974-2982.
19. Paban V, Alescio-Lautier B, Devigne C, Soumireu-Mourat B. Fos protein expression induced by intracerebroventricular injection of vasopressin in unconditioned and conditioned mice. Brain Res 1999; 825: 115-131.
20. Kita I, Yoshida Y, Nishino S. An activation of parvocellular oxytocinergic neurons in the paraventricular nucleus in oxytocin-induced yawning and penile erection. Neurosci Res 2006; 54: 269-275.
21. Wakerley JB, Terenzi MG, Housham SJ, Jiang QB, Ingram CD. Electrophysiological effects of oxytocin within the bed nuclei of the stria terminalis: influence of reproductive stage and ovarian steroids. Prog Brain Res 1998; 119: 321-334.
22. Ludwig M, Leng G. Autoinhibition of supraoptic nucleus vasopressin neurons in vivo: a combined retrodialysis/electrophysiological study in rats. Eur J Neurosci 1997; 9: 2532-2540.
23. Gouzenes L, Desarmenien MG, Hussy N, Richard P, Moos FC. Vasopressin regularizes the phasic firing pattern of rat hypothalamic magnocellular vasopressin neurons. J Neurosci 1998; 18: 1879-1885.
24. Tobin VA, Hashimoto H, Wacker DW, Takayanagi Y, Langnaese K, Caquineau C, Noack J, Landgraf R, Onaka T, Leng G, Meddle SL, Engelmann M, Ludwig M. An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature 2010; 464: 413-417.
25. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008; 322: 900-904.
26. Goodson JL. Nonapeptides and the evolutionary patterning of sociality. Prog Brain Res 2008; 170: 3-15.
27. Young LJ, Wang Z. The neurobiology of pair bonding. Nat Neurosci 2004; 7: 1048-1054.
28. Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, Yun CR, Solomon M, Jacob S, Mendoza SP. Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatry 2012; Oct 15. pii: S0006-3223(12)00800-1. doi: 10.1016/j.biopsych.2012.08.025. [Epub ahead of print].
29. Lukas M, Neumann ID. Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology 2012; 62: 398-405.
30. Ionescu IA, Dine J, Yen YC, Buell DR, Herrmann L, Holsboer F, Eder M, Landgraf R, Schmidt U. Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology 2012; 37: 1323-1337.
31. Jiang M, Griff ER, Ennis M, Zimmer LA, Shipley MT. Activation of locus coeruleus enhances the responses of olfactory bulb mitral cells to weak olfactory nerve input. J Neurosci 1996; 16: 6319-6329.
32. Engelmann M, Hadicke J, Noack J. Testing declarative memory in laboratory rats and mice using the nonconditioned social discrimination procedure. Nat Protoc 2011; 6: 1152-1162.
33. Wall PM, Messier C. Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neurosci Biobehav Rev 2001; 25: 275-286.
34. Denenberg VH. Open-field behavior in the rat: what does it mean? Ann NY Acad Sci 1969; 159: 852-859.
35. Landgraf R, Neumann I, Holsboer F, Pittman QJ. Interleukin-1 beta stimulates both central and peripheral release of vasopressin and oxytocin in the rat. Eur J Neurosci 1995; 7: 592-798.
36. Le Moal M, Dantzer R, Michaud B, Koob GF. Centrally injected arginine vasopressin (AVP) facilitates social memory in rats. Neurosci Lett 1987; 77: 353-359.
37. Dantzer R, Bluthe RM, Koob GF, Le Moal M. Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology 1987; 91: 363-368.
38. Engelmann M, Landgraf R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav 1994; 55: 145-149.
39. Dluzen DE, Muraoka S, Engelmann M, Landgraf R. The effects of infusion of arginine vasopressin, oxytocin, or their antagonists into the olfactory bulb upon social recognition responses in male rats. Peptides 1998; 19: 999-1005.
40. Appenrodt E, Schnabel R, Schwarzberg H. Vasopressin administration modulates anxiety-related behavior in rats. Physiol Behav 1998; 64: 543-547.
41. Klimkiewicz T. Memory effects of arginine vasopressin (AVP) and [7-9] fragment of its peptide chain in rats. Acta Neurobiol Exp 2001; 61: 267-276.
42. Ganten D, Unger T, Lang RE. The dual role of angiotensin and vasopressin as plasma hormones and neuropeptides in cardiovascular regulation. J Pharmacol 1985; 16: 51-68.
43. Petersson M, Uvnas-Moberg K. Effects of an acute stressor on blood pressure and heart rate in rats pretreated with intracerebroventricular oxytocin injections. Psychoneuroendocrinology 2007; 32: 959-965.
44. Poulin P, Komulainen A, Takahashi Y, Pittman QJ. Enhanced pressor responses to ICV vasopressin after pretreatment with oxytocin. Am J Physiol 1994; 266: R592-R598.
45. Gutkowska J, Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol 2012; 24: 599-608.
46. Lloyd S. Changes in the vascular responses of the rat during pregnancy. J Physiol 1959; 149: 586-592.
47. Chen YL, Shepherd C, Spinelli W, Lai FM. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors. Eur J Pharmacol 1999; 376: 45-51.
48. Costa ESRH, Pereira-Junior PP, Oliveira PF, Olivares EL, Werneck-de-Castro JP, Mello DB, Nascimento JH, Campos-de-Carvalho AC. Cardiac effects of oxytocin: is there a role for this peptide in cardiovascular homeostasis? Regul Pept 2005; 132: 107-112.
49. Petty MA, Lang RE, Unger T, Ganten D. The cardiovascular effects of oxytocin in conscious male rats. Eur J Pharmacol 1985; 112: 203-210.
50. Huntingford PJ. Intranasal use of synthetic oxytocin in management of breast-feeding. Br Med J 1961; 1: 709-711.
51. Hoover RT. Intranasal oxytocin in eighteen hundred patients. A study on its safety as used in a community hospital. Am J Obstet Gynecol 1971; 110: 788-794.
52. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36: 1114-1126.
53. Le Moal M, Koob GF, Koda LY, Bloom FE, Manning M, Sawyer WH, Rivier J. Vasopressor receptor antagonist prevents behavioural effects of vasopressin. Nature 1981; 291: 491-493.
54. Thorne RG, Frey WH II. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001; 40: 907-946.
55. Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9: S5.
56. de Wied D, Gaffori O, van Ree JM, de Jong W. Central target for the behavioural effects of vasopressin neuropeptides. Nature 1984; 308: 276-278.
57. Danguir J. Sleep deficits in rats with hereditary diabetes insipidus. Nature 1983; 304: 163-164.
58. Mens WB, Witter A, van Wimersma Greidanus TB. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res 1983; 262: 143-149.
59. Hernando F, Schoots O, Lolait SJ, Burbach JP. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001; 142: 1659-1668.
60. Knopf PM, Cserr HF, Nolan SC, Wu TY, Harling-Berg CJ. Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Neuropathol Appl Neurobiol 1995; 21: 175-180.
61. Wioland MA, Fleury-Feith J, Corlieu P, Commo F, Monceaux G, Lacau-St-Guily J, Bernaudin JF. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 2000; 48: 1215-1222.
62. Graff CL, Pollack GM. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 2003; 20: 1225-1230.
63. Kandimalla KK, Donovan MD. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm Res 2005; 22: 1121-1128.
64. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res 1992; 9: 1-9.
65. Minn A, Leclerc S, Heydel JM, Minn AL, Denizcot C, Cattarelli M, Netter P, Gradinaru D. Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier. J Drug Target 2002; 10: 285-296.
66. 125I]RB 129. Neuroscience 2001; 105: 479-488.
67. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-496.
68. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH II. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004; 151: 66-77.
69. Watelet JB, Strolin-Benedetti M, Whomsley R. Defence mechanisms of olfactory neuro-epithelium: mucosa regeneration, metabolising enzymes and transporters. B-Ent 2009; 5: 21-37.
70. Yu Q, Ji R, Gao X, Fu J, Guo W, Song X, Zhao X, Burnstock G, Shi X, He C, Xiang Z. Oxytocin is expressed by both intrinsic sensory and secretomotor neurons in the enteric nervous system of guinea pig. Cell Tissue Res 2011; 344: 227-237.
71. Porges SW. The Polyvagal Theory: Neurohypophysiological Foundations of Emotions, Attachment, Communication, and Self-Regulation. New York, NY: WW Norton, 2011.
72. Levasseur G, Baly C, Grebert D, Durieux D, Salesse R, Caillol M. Anatomical and functional evidence for a role of arginine-vasopressin (AVP) in rat olfactory epithelium cells. Eur J Neurosci 2004; 20: 658-670.
73. Lund VJ. Nasal physiology: neurochemical receptors, nasal cycle, and ciliary action. Allergy Asthma Proc 1996; 17: 179-184.